Abstract
We evaluated short-term results of infliximab therapy in 16 patients with rheumatoid arthritis. The subjects consisted of two males and 14 females, with an average age of 56.8±10.8 years. We studied CRP, DAS28 (CRP), and secondary invalidness. Swelling and joint pain improved in the first stages of the administration, decreasing at 2, 6, 14 weeks, although the CRP level was 3.9±2.7mg/dl remaining from before administration. However, decrease was not significant, and it tended to concentrate in the final stage of investigations. DAS28(CRP) was also similar. Three cases failed for secondary invalidness. Infliximab therapy requires more investigations with regard to shortening of administrative interval and increase of dose in the future.
